Recombinant T-cell epitope conjugation: A new approach for Dermatophagoides hypoallergen design.
Animals
Humans
Mice
Allergens
Antigens, Dermatophagoides
/ immunology
Arthropod Proteins
Dermatophagoides pteronyssinus
Epitopes, T-Lymphocyte
/ chemistry
Hypersensitivity
/ drug therapy
Immunoglobulin E
Interleukin-10
Interleukin-4
Interleukin-5
Leukocytes, Mononuclear
Pyroglyphidae
Recombinant Proteins
/ genetics
Immunotherapy
/ methods
Dermatophagoides pteronyssinus
allergen-specific immunotherapy
hypoallergen
immunogenicity
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
15
09
2022
received:
10
05
2022
accepted:
25
09
2022
pubmed:
1
10
2022
medline:
18
2
2023
entrez:
30
9
2022
Statut:
ppublish
Résumé
Allergen-specific immunotherapy (AIT) is the only clinical approach that can potentially cure some allergic diseases by inducing immunological tolerance. Dermatophagoides pteronyssinus is considered as the most important source of mite allergens worldwide, with high sensitization rates for the major allergens Der p 1, Der p 2 and Der p 23. The aim of this work is to generate a hypoallergenic hybrid molecule containing T-cell epitopes from these three major allergens. The hybrid protein termed Der p 2231 containing T-cell epitopes was purified by affinity chromatography. The human IgE reactivity was verified by comparing those with the parental allergens. The hybrid was also characterized immunologically through an in vivo mice model. The hybrid rDer p 2231 stimulated in peripheral blood mononuclear cells (PBMCs) isolated from allergic patients with higher levels of IL- 2, IL-10, IL-15 and IFN-γ, as well as lower levels of IL-4, IL-5, IL-13, TNF-α and GM-CSF. The use of hybrid molecules as a therapeutic model in D. pteronyssinus allergic mice led to the reduction of IgE production and lower eosinophilic peroxidase activity in the airways. We found increased levels of IgG antibodies that blocked the IgE binding to the parental allergens in the serum of allergic patients. Furthermore, the stimulation of splenocytes from mice treated with rDer p 2231 induced higher levels of IL-10 and IFN-γ and decreased the secretion of IL-4 and IL-5, when compared with parental allergens and D. pteronyssinus extract. rDer p 2231 has the potential to be used in AIT in patients co-sensitized with D. pteronyssinus major allergens, once it was able to reduce IgE production, inducing allergen-specific blocking antibodies, restoring and balancing Th1/Th2 immune responses, and inducing regulatory T-cells.
Sections du résumé
BACKGROUND
Allergen-specific immunotherapy (AIT) is the only clinical approach that can potentially cure some allergic diseases by inducing immunological tolerance. Dermatophagoides pteronyssinus is considered as the most important source of mite allergens worldwide, with high sensitization rates for the major allergens Der p 1, Der p 2 and Der p 23. The aim of this work is to generate a hypoallergenic hybrid molecule containing T-cell epitopes from these three major allergens.
METHODS
The hybrid protein termed Der p 2231 containing T-cell epitopes was purified by affinity chromatography. The human IgE reactivity was verified by comparing those with the parental allergens. The hybrid was also characterized immunologically through an in vivo mice model.
RESULTS
The hybrid rDer p 2231 stimulated in peripheral blood mononuclear cells (PBMCs) isolated from allergic patients with higher levels of IL- 2, IL-10, IL-15 and IFN-γ, as well as lower levels of IL-4, IL-5, IL-13, TNF-α and GM-CSF. The use of hybrid molecules as a therapeutic model in D. pteronyssinus allergic mice led to the reduction of IgE production and lower eosinophilic peroxidase activity in the airways. We found increased levels of IgG antibodies that blocked the IgE binding to the parental allergens in the serum of allergic patients. Furthermore, the stimulation of splenocytes from mice treated with rDer p 2231 induced higher levels of IL-10 and IFN-γ and decreased the secretion of IL-4 and IL-5, when compared with parental allergens and D. pteronyssinus extract.
CONCLUSIONS
rDer p 2231 has the potential to be used in AIT in patients co-sensitized with D. pteronyssinus major allergens, once it was able to reduce IgE production, inducing allergen-specific blocking antibodies, restoring and balancing Th1/Th2 immune responses, and inducing regulatory T-cells.
Substances chimiques
Allergens
0
Antigens, Dermatophagoides
0
Arthropod Proteins
0
Epitopes, T-Lymphocyte
0
Immunoglobulin E
37341-29-0
Interleukin-10
130068-27-8
Interleukin-4
207137-56-2
Interleukin-5
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198-209Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485-1498.
Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717-725.e715.
Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy. 2013;3(1):17.
Prickett SR, Rolland JM, O'Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015;45(6):1015-1026.
Huang HJ, Curin M, Banerjee S, et al. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. Allergy. 2019;74(12):2461-2478.
Couroux P, Patel D, Armstrong K, Larche M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974-981.
Gupta K, Kumar S, Das M, Dwivedi PD. Peptide based immunotherapy: a pivotal tool for allergy treatment. Int Immunopharmacol. 2014;19(2):391-398.
Silva ESD, Pinheiro CS, Pacheco LGC, Alcantara-Neves NM. Dermatophagoides spp. hypoallergens design: what has been achieved so far? Expert Opin Ther Pat. 2020;30(3):163-177.
Zhao BB, Diao JD, Liu ZM, Li CP, Jiang YX. Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy. Int J Clin Exp Pathol. 2014;7(7):3608-3619.
Martinez D, Cantillo JF, Herazo H, et al. Characterization of a hybrid protein designed with segments of allergens from Blomia tropicalis and Dermatophagoides pteronyssinus. Immunol Lett. 2018;196:103-112.
Chen KW, Blatt K, Thomas WR, et al. Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. J Allergy Clin Immunol. 2012;130(2):435-443.e434.
Asturias JA, Ibarrola I, Arilla MC, et al. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin Exp Allergy. 2009;39(7):1088-1098.
Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol. 2011;127(3):608-15.e1-5.
Portnoy J, Miller JD, Williams PB, et al. Environmental assessment and exposure control of dust mites: a practice parameter. Ann Allergy Asthma Immunol. 2013;111(6):465-507.
da Silva DR, Binotti RS, da Silva CM, de Oliveira CH, Condino-Neto A, de Capitani EM. Mites in dust samples from mattress surfaces from single beds or cribs in the south Brazilian city of Londrina. Pediatr Allergy Immunol. 2005;16(2):132-136.
Caraballo L, Valenta R, Puerta L, et al. The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources. World Allergy Organ J. 2020;13(5):100118.
Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017;139(2):541-549.e548.
Kowal K, Pampuch A, Siergiejko G, et al. Sensitization to major Dermatophagoides pteronyssinus allergens in house dust mite allergic patients from North Eastern Poland developing rhinitis or asthma. Adv Med Sci. 2020;65(2):304-309.
Hinz D, Oseroff C, Pham J, Sidney J, Peters B, Sette A. Definition of a pool of epitopes that recapitulates the T cell reactivity against major house dust mite allergens. Clin Exp Allergy. 2015;45(10):1601-1612.
Kalita P, Lyngdoh DL, Padhi AK, Shukla H, Tripathi T. Development of multi-epitope driven subunit vaccine against Fasciola gigantica using immunoinformatics approach. Int J Biol Macromol. 2019;138:224-233.
Kallberg M, Margaryan G, Wang S, Ma J, Xu J. RaptorX server: a resource for template-based protein structure modeling. Methods Mol Biol. 2014;1137:17-27.
Santos da Silva E, Marques Ponte JC, Barbosa da Silva M, et al. Proteomic analysis reveals allergen variability among breeds of the dust mite blomia tropicalis. Int Arch Allergy Immunol. 2019;180(3):159-172.
da Silva ES, Aglas L, Pinheiro CS, et al. A hybrid of two major Blomia tropicalis allergens as an allergy vaccine candidate. Clin Exp Allergy. 2020;50(7):835-847.
Barreto ML, Cunha SS, Alcantara-Neves N, et al. Risk factors and immunological pathways for asthma and other allergic diseases in children: background and methodology of a longitudinal study in a large urban center in Northeastern Brazil (Salvador-SCAALA study). BMC Pulm Med. 2006;6:15.
Figueiredo CA, Amorim LD, Alcantara-Neves NM, et al. Environmental conditions, immunologic phenotypes, atopy, and asthma: new evidence of how the hygiene hypothesis operates in Latin America. J Allergy Clin Immunol. 2013;131(4):1064-1068 e1061.
Santos LN, Gallo MB, Silva ES, et al. A proteomic approach to identify proteins from Trichuris trichiura extract with immunomodulatory effects. Parasite Immunol. 2013;35(5-6):188-193.
Moreno Amor AL, Santos LN, Alcantara Galvao A, et al. Candidin and trichophytin stimulate the production of Th1 and regulatory cytokines by peripheral blood mononuclear cells: implication for their use as adjuvants in immunotherapy. Immunotherapy. 2014;6(12):1255-1264.
Santos Serafim Machado M, Ferreira Silva HB, Rios R, et al. The anti-allergic activity of Cymbopogon citratus is mediated via inhibition of nuclear factor kappa B (Nf-Kappab) activation. BMC Complement Altern Med. 2015;15:168.
Oliveira TT, Campos KM, Cerqueira-Lima AT, et al. Potential therapeutic effect of Allium cepa L. and quercetin in a murine model of Blomia tropicalis induced asthma. Daru. 2015;23:18.
Costa RS, Carneiro TC, Cerqueira-Lima AT, et al. Ocimum gratissimum Linn. and rosmarinic acid, attenuate eosinophilic airway inflammation in an experimental model of respiratory allergy to Blomia tropicalis. Int Immunopharmacol. 2012;13(1):126-134.
Baqueiro T, Russo M, Silva VM, et al. Respiratory allergy to Blomia tropicalis: immune response in four syngeneic mouse strains and assessment of a low allergen-dose, short-term experimental model. Respir Res. 2010;11:51.
Batard T, Baron-Bodo V, Martelet A, et al. Patterns of IgE sensitization in house dust mite-allergic patients: implications for allergen immunotherapy. Allergy. 2016;71(2):220-229.
Soh WT, Le Mignon M, Suratannon N, et al. The house dust mite major allergen Der p 23 displays o-glycan-independent IgE reactivities but no chitin-binding activity. Int Arch Allergy Immunol. 2015;168(3):150-160.
Mueller GA, Randall TA, Glesner J, et al. Serological, genomic and structural analyses of the major mite allergen Der p 23. Clin Exp Allergy. 2016;46(2):365-376.
Pinheiro CS, Silva ES, de Andrade Belitardo EMM, et al. En route to personalized medicine: uncovering distinct IgE reactivity pattern to house dust mite components in Brazilian and Austrian allergic patients. Clin Transl Allergy. 2021;11(1):e12004.
Schulke S. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front Immunol. 2018;9:455.
Branchett WJ, Stolting H, Oliver RA, et al. A T cell-myeloid IL-10 axis regulates pathogenic IFN-gamma-dependent immunity in a mouse model of type 2-low asthma. J Allergy Clin Immunol. 2020;145(2):666-678.e669.
Wambre E. Effect of allergen-specific immunotherapy on CD4+ T cells. Curr Opin Allergy Clin Immunol. 2015;15(6):581-587.
Boonpiyathad T, Sokolowska M, Morita H, et al. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy. Allergy. 2019;74(5):976-985.
Zhang YZ, Luo J, Wang ZH, Wang J. Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. Am J Otolaryngol. 2019;40(5):755-760.
De Amici M, Puggioni F, Casali L, Alesina R. Variations in serum levels of interleukin (IL)-1beta, IL-2, IL-6, and tumor necrosis factor-alpha during specific immunotherapy. Ann Allergy Asthma Immunol. 2001;86(3):311-313.
Yin GQ, Jiang WH, Wu PQ, He CH, Chen RS, Deng L. Clinical evaluation of sublingual administration of dust mite drops in the treatment of allergic asthma and allergic rhinitis of children. Eur Rev Med Pharmacol Sci. 2016;20(20):4348-4353.
Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004;113(6):1025-1034. quiz 1035.
Komai-Koma M, McKay A, Thomson L, et al. Immuno-regulatory cytokines in asthma: IL-15 and IL-13 in induced sputum. Clin Exp Allergy. 2001;31(9):1441-1448.
Yan L, Xiao-Ling S, Zheng-Yan C, Guo-Ping L, Sen Z, Zhuang C. HSP70/CD80 DNA vaccine inhibits airway remodeling by regulating the transcription factors T-bet and GATA-3 in a murine model of chronic asthma. Arch Med Sci. 2013;9(5):906-915.
Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy. 2016;46(9):1139-1151.
Gould HJ, Ramadani F. IgE responses in mouse and man and the persistence of IgE memory. Trends Immunol. 2015;36(1):40-48.
Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60(12):1012-1018.
Dejager L, Dendoncker K, Eggermont M, et al. Neutralizing TNFalpha restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 2015;8(6):1212-1225.
Nobs SP, Kayhan M, Kopf M. GM-CSF intrinsically controls eosinophil accumulation in the setting of allergic airway inflammation. J Allergy Clin Immunol. 2019;143(4):1513-1524.e2.
Willart MA, Deswarte K, Pouliot P, et al. Interleukin-1alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med. 2012;209(8):1505-1517.
Ben-Sasson SZ, Hu-Li J, Quiel J, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A. 2009;106(17):7119-7124.
Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10(2):89-102.
Willart M, Hammad H. Lung dendritic cell-epithelial cell crosstalk in Th2 responses to allergens. Curr Opin Immunol. 2011;23(6):772-777.
Akiki Z, Rava M, Diaz Gil O, et al. Serum cytokine profiles as predictors of asthma control in adults from the EGEA study. Respir Med. 2017;125:57-64.
Domdey A, Liu A, Millner A, et al. The T cell response to major grass allergens is regulated and includes IL-10 production in atopic but not in non-atopic subjects. Int Arch Allergy Immunol. 2010;152(3):243-254.
Banerjee S, Weber M, Blatt K, et al. Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol. 2014;192(10):4867-4875.
Mrkic I, Minic R, Popovic D, Zivkovic I, Gavrovic-Jankulovic M. Newly designed hemagglutinin-Der p 2 chimera is a potential candidate for allergen specific immunotherapy. Life Sci. 2018;213:158-165.
Choi Y, Jeon H, Yang EA, Yoon JS, Kim HH. Nasal eosinophilia and eosinophil peroxidase in children and adolescents with rhinitis. Korean J Pediatr. 2019;62(9):353-359.
Hofer H, Asam C, Hauser M, et al. Tackling Bet v 1 and associated food allergies with a single hybrid protein. J Allergy Clin Immunol. 2017;140(2):525-533.e510.